Cancer Immunotherapy

Immune Responses Elicited in IL-2 Gene Therapy Trial of Neuroblastoma

Published in Cancer Weekly, October 5th, 1998

Promising results were obtained in an interleukin-2 (IL-2) gene therapy trial of neuroblastoma patients.

Several different murine models have demonstrated that the immunogenicity of tumor cells can be increased by transduction with a range of immunostimulatory genes which induce an immune response that causes regression of pre-existing unmodified tumor cells. In order to investigate the relevance of these animal models to clinical situations with pediatric patients, Laura Bowman and colleagues from St. Jude Children's Research Hospital and the Memphis College of Medicine, Tennessee, used autologous unirradiated tumor cells transduced with an adenovirus-IL-2 to immunize...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1998-10-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry